sebelipase alfa: clinical use

Prescribing considerations

• Treatment should be supervised by a clinician experienced in lysosomal acid lipase deficiency, metabolic disorders or chronic liver disease.
• Ensure staff and facilities can recognise and manage anaphylaxis and severe infusion reactions.
• Consider sodium exposure in patients following a controlled-sodium diet.
• Record the product name and batch number to maintain biological-medicine traceability.

Contraindications and cautions

• Life-threatening hypersensitivity to sebelipase alfa when rechallenge has been unsuccessful.
• Life-threatening hypersensitivity to egg or any excipient.

Monitoring

• Observe closely for hypersensitivity during and after initial administration and whenever clinically indicated.
• Monitor clinical and biochemical response, including growth, liver tests, lipid profile, organ size and relevant gastrointestinal features.
• Test for anti-drug antibodies after severe infusion reactions or an unexplained lack or loss of effect.
• Be aware that transient, usually asymptomatic increases in circulating cholesterol and triglycerides may occur after treatment starts.

Clinical pharmacology

Sebelipase alfa is recombinant human lysosomal acid lipase. Glycan-mediated receptor binding enables cellular uptake into lysosomes, where it hydrolyses cholesteryl esters and triglycerides.

Formulation and product differences

• The selected product is a single-use concentrate requiring aseptic dilution with sodium chloride infusion solution.
• It is produced using recombinant technology in egg white and may contain traces of egg proteins.
• Excipients include human serum albumin and sodium compounds.
• Unopened vials require refrigerated, light-protected storage and must not be frozen or shaken.